Per NCCN and ASCO guidelines, liquid biopsy (ctDNA) is now preferred over tissue biopsy for detecting ESR1 mutations. Its advantages include being less invasive with a faster turnaround, but most importantly, it effectively captures the dynamic, evolving nature of tumors, which is characteristic of acquired ESR1 mutations.
For the complex scenario of patients with both ESR1 and PIK3CA mutations, a combination approach shows significant promise. The AVERA trial, combining an oral SERD (gerodestrant) with an mTOR inhibitor (everolimus), addressed both pathways and demonstrated a median progression-free survival of over 10 months, suggesting a superior strategy to targeting a single mutation.
With several new oral endocrine agents showing similar efficacy for ESR1-mutated breast cancer, clinicians' choices are driven by practical factors. Treatment selection hinges on tolerability (e.g., vepdegestrant's QT prolongation risk) and familiarity with an agent's real-world performance, rather than marginal differences in trial data.
An acquired ESR1 mutation in metastatic breast cancer, while indicating resistance to prior therapy, also confirms the tumor remains dependent on the estrogen receptor pathway. This paradoxical finding makes the mutation an ideal biomarker for predicting success with next-generation endocrine agents like oral SERDs.
Subgroup analysis from the EMERALD trial reveals a key predictive biomarker: patients with ESR1-mutated breast cancer who benefited from first-line endocrine therapy plus a CDK4/6 inhibitor for over 12 months experienced significantly better progression-free survival on second-line elacestrant, indicating retained endocrine sensitivity.